Cited In for PMID: 23243595

Year	Number of Results
2012	1
2013	3
2014	2
2018	2
2019	1
2021	1
2023	1
2024	0

1

Studying the role of the immune system on the antitumor activity of a Hedgehog inhibitor against murine osteosarcoma.

Paget C, Duret H, Ngiow SF, Kansara M, Thomas DM, Smyth MJ. Paget C, et al. Oncoimmunology. 2012 Nov 1;1(8):1313-1322. doi: 10.4161/onci.21680. Oncoimmunology. 2012. PMID: 23243595 Free PMC article.

2

Ligand-dependent hedgehog signaling maintains an undifferentiated, malignant osteosarcoma phenotype.

Vaghjiani VG, Cochrane CR, Jayasekara WSN, Chong WC, Szczepny A, Kumar B, Martelotto LG, McCaw A, Carey K, Kansara M, Thomas DM, Walkley C, Mudge S, Gough DJ, Downie PA, Peacock CD, Matsui W, Watkins DN, Cain JE. Vaghjiani VG, et al. Oncogene. 2023 Nov;42(47):3529-3541. doi: 10.1038/s41388-023-02864-7. Epub 2023 Oct 16. Oncogene. 2023. PMID: 37845394 Free PMC article.

3

Combination immunotherapy using G-CSF and oncolytic virotherapy reduces tumor growth in osteosarcoma.

Morales-Molina A, Gambera S, Leo A, García-Castro J. Morales-Molina A, et al. J Immunother Cancer. 2021 Mar;9(3):e001703. doi: 10.1136/jitc-2020-001703. J Immunother Cancer. 2021. PMID: 33737338 Free PMC article.

4

Effect of RAB31 silencing on osteosarcoma cell proliferation and migration through the Hedgehog signaling pathway.

Yu Q, Li D, Wang D, Hu CM, Sun Y, Tang Y, Shi G. Yu Q, et al. J Bone Miner Metab. 2019 Jul;37(4):594-606. doi: 10.1007/s00774-018-0961-9. Epub 2018 Nov 23. J Bone Miner Metab. 2019. PMID: 30470957 Retracted.

5

Hedgehog signalling in the tumourigenesis and metastasis of osteosarcoma, and its potential value in the clinical therapy of osteosarcoma.

Yao Z, Han L, Chen Y, He F, Sun B, Kamar S, Zhang Y, Yang Y, Wang C, Yang Z. Yao Z, et al. Cell Death Dis. 2018 Jun 13;9(6):701. doi: 10.1038/s41419-018-0647-1. Cell Death Dis. 2018. PMID: 29899399 Free PMC article. Review.

6

Translational biology of osteosarcoma.

Kansara M, Teng MW, Smyth MJ, Thomas DM. Kansara M, et al. Nat Rev Cancer. 2014 Nov;14(11):722-35. doi: 10.1038/nrc3838. Epub 2014 Oct 16. Nat Rev Cancer. 2014. PMID: 25319867 Review.

7

Immune effectors required for the therapeutic activity of vorinostat.

Kepp O, Galluzzi L, Kroemer G. Kepp O, et al. Oncoimmunology. 2013 Nov 1;2(11):e27157. doi: 10.4161/onci.27157. Epub 2013 Nov 13. Oncoimmunology. 2013. PMID: 24475375 Free PMC article. No abstract available.

8

Current therapeutic strategies and novel approaches in osteosarcoma.

Ando K, Heymann MF, Stresing V, Mori K, Rédini F, Heymann D. Ando K, et al. Cancers (Basel). 2013 May 24;5(2):591-616. doi: 10.3390/cancers5020591. Cancers (Basel). 2013. PMID: 24216993 Free PMC article.

9

Immunogenic calreticulin exposure occurs through a phylogenetically conserved stress pathway involving the chemokine CXCL8.

Sukkurwala AQ, Martins I, Wang Y, Schlemmer F, Ruckenstuhl C, Durchschlag M, Michaud M, Senovilla L, Sistigu A, Ma Y, Vacchelli E, Sulpice E, Gidrol X, Zitvogel L, Madeo F, Galluzzi L, Kepp O, Kroemer G. Sukkurwala AQ, et al. Cell Death Differ. 2014 Jan;21(1):59-68. doi: 10.1038/cdd.2013.73. Epub 2013 Jun 21. Cell Death Differ. 2014. PMID: 23787997 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

9 results

Results by year